Adynxx Inc. (ADYX)
Adynxx Reports Third Quarter 2019 Financial Results
Adynxx Reports Third Quarter 2019 Financial Results
Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic
Award of More than $600K Will Support Advancement of AYX2 for Chronic Pain to IND-Enabling Studies
Adynxx readies $15M stock offering
Adynxx (OTC:ADYX) has filed a preliminary prospectus for a $15M public offering of common stock or pre-funded warrants. Price, volume and terms have yet to be announced.
Adynxx Reports Second Quarter 2019 Financial Results
Nasdaq slumps more than 200 points as Dow is saddled with 540-point decline
COMP | A complete NASDAQ Composite Index index overview by MarketWatch. View stock market news, stock market data and trading information.
Nasdaq Composite hits record intraday high, up 86.04 points, or 1% to 8324.58
COMP | A complete NASDAQ Composite Index index overview by MarketWatch. View stock market news, stock market data and trading information.
Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market
Adynxx Stock to Move to OTC Market Following Receipt of Nasdaq Delisting Notice
Company on Track with All Business Operations and Clinical Development Plans for Brivoligide While Pursuing Options to Comply with Nasdaq’s Initial Listing Requirements
Adynxx sets May 29 as payment date of special cash dividend
Adynxx (NASDAQ:ADYX) announces May 29, 2019 as payment date for the special cash dividend of $1.05 per share announced by Alliqua Biomedical, on April 11, 2019. Also, the Company plans to initiate tw